

EVALUATING THE SPECIFICITY OF [18F]UCB-H FOR THE ISOFORM SV2A, COMPARED WITH SV2B AND SV2C


miCRO imAƏInG laboratory Maria Elisa Serrano Navacerrada, Joël Aerts, Mohamed Ali Bahri, Guillaume Becker, Fabrice Giacomelli, Christian Lemaire, André Luxen, Joël Mercier, Nathalie Mestdagh, Frédéric Mievis, Alain Plenevaux, Eric Salmon, Corentin Warnier

GIGA-Research, CRC In vivo Imaging, Université de Liège

Introduction


SV2A is a SV2 isoform protein involved in the synaptic vesicle trafficking and in brain process like the epilepsy (1, 2). [18F]UCB-H was developed like a tool to study the role of this isoform with neuroimaging techniques (3, 4).


The **objective** of this study was to **evaluate the specificity of this radiotracer to the isoform SV2A** comparing with the others, through a competition assay.



Results


EX-VIVO AUTORADIOGRAPHY






[¹⁸F]UCB-H uptake after a pretreatment with the ligands for SV2 isoforms. Histograms represent the mean and SD (n=5). Data, expressed in ROD (Relative Optical Density), were normalized to SUV (Standard Uptake Value). Two-ways ANOVA and Bonferroni post-hoc test were done, with *p<0.05, ***p<0.001.

mPET IMAGING





Histograms represent the mean and SD (n=5) after analysing the AUC (Area under the curve of images obtained with mPET technique during 1 hour of dynamic acquisition). Data were normalized to SUV (Standard Uptake Value). Two-ways ANOVA and Bonferroni post-hoc test were done, with ***p<0.001 between the group treated with Keppra and the rest of groups.

Conclusion

An affinity between the ligands UCB068 and UCB054, and the receptor for the isoform SV2A exists but it is only detected during the first 5 minutes, being certainly due to a nonspecific binding. This binding is not strong enough to show a direct competition with the radiotracer during a mPET acquisition.

These results allow us to conclude that [18F]UCB-H is a suitable radiotracer for the imaging of the isoform SV2A in vivo.

FRRS Université Ug

This research was supported by FRS FNRS, Walloon Region and UCB Pharma. Alain Plenevaux is research director of the FRS-FNRS Belgium.

Contact : meserrano@ulg.ac.be

Van Vliet et al., 2009.Epilepsia 2) Crèvecœur et al., 2013.BMC Neurosci.
Bretin et al., 2013.EJNMMI Res 4) Bretin et al., 2015.Mol Imaging Biol